AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Accessnewswire

Published November 5, 2026

BioAdaptives to Acquire Xycota Biosciences to Pursue the Potential of At Home Psilocybin Treatment

Read the full story at Accessnewswire

This release is not an offer to sell securities. INVESTOR & MEDIA CONTACT. BioAdaptives, Inc: Drew@BioAdaptives.com 702-659-8829. X - @BioAdaptivesInc.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic press release